Skip to main
  1. Stocks
  2. Travere Therapeutics
  3. Forecast
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is viewed positively because FILSPARI is demonstrating strong commercial momentum, with 2Q26 revenue of $141.1M and 2,012 new patient start forms, while physician surveys point to rising use in both IgAN and FSGS. The newly allowed USPTO patent for FSGS methods, expected to extend coverage into October 2037 and match the IgAN patent, materially reduces exclusivity risk around the franchise’s main growth driver. In addition, the planned CEO transition to Bradley Campbell and the continued advancement of pegtibatinase and civorebrutinib give the company a credible path to diversify beyond FILSPARI while preserving execution strength.

Bears say

Travere Therapeutics is facing a fundamentally fragile outlook despite its $489.2M cash, cash equivalents and marketable securities at the end of 1Q 2026, because that balance may only support operations into the future and does not eliminate financing risk. The company may need to access the capital markets to fund its portfolio and commercialization efforts, and any follow-on stock offering could dilute current shareholders if additional capital is raised. Beyond financing, delays or setbacks in commercializing Filspari or pegtibatinase could materially reduce sales potential, while constrained capital market access would limit its ability to advance development or bring products to market.

Travere Therapeutics (TVTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction

Get the latest Travere Therapeutics (TVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Travere Therapeutics (TVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 10 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction

Get the latest Travere Therapeutics (TVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Travere Therapeutics (TVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TVTX stock data and trends